LENZ Therapeutics, Inc. (LENZ) Common Equity (2022 - 2023)
LENZ Therapeutics (LENZ) has disclosed Common Equity for 2 consecutive years, with -$69.6 million as the latest value for Q3 2023.
- On a quarterly basis, Common Equity fell 121.98% to -$69.6 million in Q3 2023 year-over-year; TTM through Sep 2023 was -$69.6 million, a 121.98% decrease, with the full-year FY2022 number at -$24.2 million, changed N/A from a year prior.
- Common Equity was -$69.6 million for Q3 2023 at LENZ Therapeutics, down from -$51.2 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $361.3 million in Q1 2022 to a low of -$69.6 million in Q3 2023.